Publications

5808 Results

Mevastatin can increase toxicity in primary AMLs exposed to standard therapeutic agents, but statin efficacy is not simply associated with ras hotspot mutations or overexpression

Authors
DL Stirewalt;FR Appelbaum;CL Willman;RA Zager;DE Banker
Journal / Conference
Leukemia Research 27:133-145
Year
2003
Research Committee(s)
Leukemia

Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: Results from an Intergroup phase II trial

Authors
ML Rothenberg;PY Liu;PS Braley;SP Wilczynski;EV Hannigan;S Wadler;G Stuart;C Jiang;M Markman;DS Alberts
Journal / Conference
Journal of Clinical Oncology 21(7):1313-1319
Year
2003
Research Committee(s)
Gynecologic
Study Number(s)
S9619

Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate and high grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349)

Authors
DW Blayney;ML LeBlanc;T Grogan;ER Gaynor;RA Chapman;CH Spiridonidis;SA Taylor;SI Bearman;TP Miller;RI Fisher
Journal / Conference
Journal of Clinical Oncology 21(13):2466-2473
Year
2003
Research Committee(s)
Lymphoma
Study Number(s)
SWOG-8903, SWOG-9349

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer

Authors
HB Grossman;RB Natale;CM Tangen;VO Speights;NJ Vogelzang;DL Trump;RW de Vere White;MF Sarosdy;DP Wood Jr;D Raghavan;ED Crawford
Journal / Conference
New England Journal of Medicine 349(9):859-866
Year
2003
Research Committee(s)
Genitourinary
Study Number(s)
SWOG-8710 (INT-0080) (EST-1887) (CALGB-8891)

Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501

Authors
WS Velasquez;D Lew;TM Grogan;CH Spiridonidis;SP Balcerzak;SR Dakhil;TP Miller;K Lanier;RA Chapman;RI Fisher
Journal / Conference
Journal of Clinical Oncology 21(10):1996-2003
Year
2003
Research Committee(s)
Lymphoma
Study Number(s)
SWOG-9501

The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial

Authors
PJ Stiff;JM Unger;SJ Forman;AR McCall;M LeBlanc;AP Nademanee;BJ Bolwell;RI Fisher
Journal / Conference
Biology of Blood and Marrow Transplantation 9:529-539
Year
2003
Research Committee(s)
Lymphoma
Study Number(s)
SWOG-9011

Cell cycle alterations in the blastoid variant of mantle cell lymphoma (MCL-BV) as detected by gene expression profiling of mantle cell lymphoma (MCL) and MCL-BV

Authors
S deVos;U Krug;WK Hofmann;GS Pinkus;SH Swerdlow;W Wachsman;TM Grogan;JW Said;HP Koeffler
Journal / Conference
Diagnostic Molecular Pathology 12(1):35-43
Year
2003
Research Committee(s)
Lymphoma
Study Number(s)
SWOG-8819

Directed indices for exploring gene expression data

Authors
M LeBlanc;C Kooperberg;TM Grogan;TP Miller
Journal / Conference
Bioinformatics 19(6):686-693
Year
2003
Research Committee(s)
Lymphoma

Tumor Origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy

Authors
ML Gulley;LJ Swinnen;KT Plaisance Jr;C Schnell;TM Grogan;BG Schneider
Journal / Conference
Transplantation 76(6):959-964
Year
2003
Research Committee(s)
Lymphoma
Study Number(s)
SWOG-9239

Determinants of prostate specific antigen (PSA) normalization in prostate cancer (PCa) patients (pts) treated with androgen deprivation (AD) on Southwest Oncology Group (SWOG) study 9346 (INT-0162).

Authors
CM Tangen;M Hussain;G Wilding;EJ Small;L Goldenberg;A Akdas;ED Crawford
Journal / Conference
Proc of the American Society of Clinical Oncology 22:396(#1591)
Year
2003
Research Committee(s)
Genitourinary
Study Number(s)
SWOG-9346